The U.S. Food and Drug Administration on Tuesday approved Ajovy, an injection made by Israeli drugmaker Teva Pharma , to help ...

The US Food and Drug Administration (FDA) has approved a label expansion to Teva’s Ajovy in certain children and adolescents, ...

FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children ...

The FDA has approved Ajovy® (fremanezumab-vfrm) for preventive treatment of episodic migraine in pediatric patients aged 6 to ...

Ajovy becomes the first-and-only calcitonin gene-related peptide agonist approved for pediatric patients aged six to 17 years ...

The sBLA for the pediatric indication is supported by data from the randomized, double-blind, placebo-controlled, phase 3 SPACE trial.

Teva Pharmaceutical has received a green light from the US regulator for its biologic Ajovy (fremanezumab) to be used for ...

Teva's Ajovy gains FDA approval for pediatric migraine prevention, offering hope for children aged 6-17 with this debilitating condition.

Teva (TEVA) stock in focus as the FDA expands label for its migraine therapy Ajovy for children and adolescents aged 6–17 years. Read more here.

Parsippany: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., has announced that the U.S. Food ...

The FDA expanded the indication for fremanezumab (Ajovy) injection for episodic migraine prevention to include children and ...

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its second-quarter 2025 financial results on Wednesday, reflecting a ...